From the editor


What’s next for vaccines?


On the web...


Keep up with the latest developments across the industry by visiting www.worldpharmaceuticals.net


World Pharmaceutical Frontiers 2021 Vol. 2


Editorial Editor Peter Littlejohns peter.littlejohns@progressivemediainternational.com Sub-editor Lizzie Waymouth Production manager Dave Stanford Group art director Henrik Williams Designer Martin Faulkner Head of content Jake Sharp


Commercial Sales manager Nathan Park


nathan.park@progressivemediainternational.com Client services executive Derek Deschamps Managing director William Crocker


World Pharmaceutical Frontiers is published by Progressive Media International.


Registered in England No. 06212740.


40-42 Hatton Garden, London, EC1N 8EB, UK Tel: +44 207 936 6400 www.worldpharmaceuticals.net


ISSN 1742-3791 © 2021


All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of the information in this publication, the publisher accepts no responsibility for errors/omissions.


The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.


Subscription records are maintained at Progressive Media International.


SUBSCRIPTIONS Single issue price: UK £38 EU €59 US $78 RoW $78 One year: Two year:


s I join as the new editor of World Pharmaceutical Frontiers, the imperative for the industry and the wider world is still very much to get shots into arms so we might return to normal life. The roll-out has become a crusade against misinformation in some countries – although that sort of terminology runs the risk of fuelling the anti-vaxx fire. Unsurprisingly, you won’t find an academic repudiation of 5G’s link to mass mind control here; it’s our position that Bill Gates has better things to do. Instead, we focus on the scale of vaccine hesitancy in the US, as well as the real reason many are reluctant to get vaccinated: fear. Not fear of control, though – mostly, people are worried about side effects and sceptical about what they perceive as a quick and dirty trial process. Experts in toxicology and allergy explain the risks and perceptions driving vaccine resistance on page 29. Elsewhere, we turn to the research side of the ongoing vaccine rush, exploring some of the DNA delivery technologies that could make vaccines easier to deliver and more effective against Covid-19 variants. India’s Zydus Cadila was first through the gates with its needle-free ZyCoV-D vaccine, but the three-dose schedule and specialised delivery device may bring their own drawbacks. Several other DNA vaccines using innovative device and formulation-driven delivery mechanisms have shown promise in clinical trials, and they’re investigated in detail in our opening feature on page 11. Undoubtedly, more and better vaccines are a reason for optimism, but some say the demand to produce them is sapping vital talent from the already skill- starved cell and gene therapy sector. As we discuss on page 36, the rise of Covid hasn’t rid the world of the usual life-threatening suspects. There’s now a path out of the pandemic, but finding a way to solve that skill shortage and scale up the production of cell and gene therapies could save countless lives in the years to come.


A Peter Littlejohns, editor


UK £58 EU €92 US $119 RoW $120 UK £93 EU €144 US $190 RoW $191


Tel: +44 845 155 9607 (local rate) Fax: +44 207 458 4032 Email: cs@progressivemediainternational.com Progressive Media International, Riverbridge House, Ground Floor, South Tower, Anchor Boulevard, Crossways Kent DA2 6SL


Printed by Stephens & George Print Group Images used under licence from Shutterstock.com


For reprint, e-print and licensing enquiries Please contact: Media Licensing Co, The Grange, 3 Waverley Road, Farnham, Surrey, GU9 8BB. Tel: +44 203 773 9320 or email info@medialicensingco.com


World Pharmaceutical Frontiers / www.worldpharmaceuticals.net 3


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65